Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck & Co's Frazier: International Business Is Only Scratching The Surface

Executive Summary

Merck & Co’s sales and EPS grow by double digits in the first quarter, with the performance of Keytruda, and growth in non-US markets, a feature of the three months.

You may also be interested in...



Merck And The 'Strange Business' Of Antibiotics

Antibacterials have been part of Merck's mission for decades, despite the market challenges, and it's expecting two new approvals this year. Infectious disease VP Joan Butterton talks about tackling those challenges and incentives that may help the industry address antimicrobial resistance.

Austria’s Apeiron To Attack COVID-19 At Its Entry Point

Apeiron Biologics has fashioned a recombinant version of the enzyme to which SARS-CoV-2 is thought to bind, and with governmental help has started a Phase II study in Austria, Germany and Denmark. 
 
 
 

 

Exscientia Links With Scripp Research’s Calibr To Apply AI To COVID-19

A transatlantic initiative is screening a US library of 15,000 pharmacologically active compounds for anti-COVID-19 activity, using artificial intelligence technologies.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125145

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel